One Step Forward, Two Steps Back: Regulatory Reform May Be Tougher On CMS Than On FDA
This article was originally published in The Pink Sheet
Executive Summary
President-Elect Trump is putting new meaning in the catch phrase “doubling down”: promising an executive order to require agencies to withdraw two old regulations any time they issue a new one. That may be a big challenge for CMS – and also complicate some aspects of FDA’s activities.
You may also be interested in...
Rulemaking Process Flawed, But Making Monograph Rules Still Needs Funding
The monograph program was "instituted really many, many decades ago. We've been trying to implement it since," says CDER Director Janet Woodcock. "We haven't had a much bigger pie to play with, so that's been one constraint that we've had to deal with," says center budget chief Donal Parks.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Cost-Based Pricing: The Real Threat Hiding In Latest US Drug Price Headlines
Bernie Sanders is back at it, getting headlines for demanding immediate price cuts to Novo’s blockbuster GLP-1 brands. But behind the familiar rhetoric is a newer threat: academic research on cost-based pricing that could one day feed into the emerging Medicare ‘negotiation’ system.